FDA Approves the Single-Dose Flu-Drug

Kathleen Kinder
Kathleen Kinder

Updated · Oct 27, 2018

SHARE:

News.Market.us is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
close
Advertiser Disclosure

At Market.us News, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us News. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

The US Food and Drug Administration has taken an important decision that would change how the season of Flu is seen in the United States. FDA has approved a single-dose drug that can be used for treating Flu. Till now, various methods were used for treating the same disease, but this drug would revolutionize the whole process by offering better results in a shorter period of time. Xofluza has been designed in such a way that a single dose would be sufficient to treat the various impacts of uncomplicated flu. It can be used for a wide age group from 12 and beyond. It’s an antivirus drug that has an impressive amount of performance as well.

“This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option,” said Scott Gottlieb, who is the FDA Commissioner. Of course, FDA believes that the drug would be a huge help for people who are suffering from the various issues of the flu. Flu is caused by the influenza virus and the drug has to be taken within 48 hours of symptoms.

Experts in the matter are really impressed by the move from FDA. In fact, some believe that it was a bit late from the part of FDA to take such a decision, which would save thousands of lives per year. This antiviral drug is much better than the current options in the market, given that Xofluza will be taking on the virus, instead of blocking the paths. This method is also expected to contract the length of the symptoms such as a headache and other issues that people suffer due to flu.

SHARE:
Kathleen Kinder

Kathleen Kinder

With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.